Concepts (242)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Middle East Respiratory Syndrome Coronavirus | 35 | 2021 | 8843 | 1.94 | Why? |
| Enterovirus Infections | 5 | 2019 | 404 | 1.43 | Why? |
| Population Surveillance | 13 | 2019 | 4967 | 1.21 | Why? |
| Respiratory Syncytial Virus Infections | 8 | 2019 | 1234 | 1.20 | Why? |
| Enterovirus D, Human | 3 | 2019 | 96 | 1.04 | Why? |
| Adenovirus Infections, Human | 2 | 2019 | 145 | 0.78 | Why? |
| Adenoviruses, Human | 2 | 2017 | 195 | 0.75 | Why? |
| Picornaviridae Infections | 3 | 2018 | 544 | 0.73 | Why? |
| Respiratory Syncytial Virus, Human | 7 | 2019 | 846 | 0.72 | Why? |
| Camelus | 8 | 2020 | 1425 | 0.67 | Why? |
| Respiratory Syncytial Virus Vaccines | 1 | 2017 | 104 | 0.63 | Why? |
| Respiratory Tract Infections | 8 | 2020 | 6817 | 0.58 | Why? |
| Saudi Arabia | 15 | 2020 | 4423 | 0.47 | Why? |
| United Arab Emirates | 7 | 2019 | 704 | 0.46 | Why? |
| Crowding | 1 | 2017 | 731 | 0.42 | Why? |
| Disease Outbreaks | 16 | 2021 | 27595 | 0.41 | Why? |
| Seasons | 6 | 2018 | 4071 | 0.41 | Why? |
| Parechovirus | 2 | 2018 | 48 | 0.36 | Why? |
| Coronavirus Infections | 42 | 2021 | 253789 | 0.35 | Why? |
| Staphylococcal Skin Infections | 1 | 2007 | 32 | 0.34 | Why? |
| Methicillin Resistance | 1 | 2007 | 77 | 0.34 | Why? |
| Metapneumovirus | 2 | 2020 | 465 | 0.30 | Why? |
| Paramyxoviridae Infections | 2 | 2020 | 364 | 0.30 | Why? |
| Child, Preschool | 19 | 2020 | 36283 | 0.30 | Why? |
| Antibodies, Viral | 10 | 2021 | 51949 | 0.28 | Why? |
| Zoonoses | 4 | 2021 | 3034 | 0.28 | Why? |
| United States | 24 | 2021 | 46150 | 0.27 | Why? |
| Molecular Diagnostic Techniques | 2 | 2017 | 4239 | 0.26 | Why? |
| Infant | 17 | 2020 | 30274 | 0.26 | Why? |
| Jordan | 5 | 2017 | 701 | 0.25 | Why? |
| Viruses | 1 | 2017 | 2238 | 0.25 | Why? |
| Infectious Disease Transmission, Professional-to-Patient | 3 | 2020 | 1316 | 0.25 | Why? |
| Genes, Viral | 3 | 2019 | 1428 | 0.25 | Why? |
| Virus Diseases | 2 | 2017 | 3779 | 0.24 | Why? |
| Child | 20 | 2021 | 70012 | 0.22 | Why? |
| Cross Infection | 9 | 2019 | 8675 | 0.21 | Why? |
| Staphylococcus aureus | 1 | 2007 | 844 | 0.21 | Why? |
| Adolescent | 19 | 2020 | 86841 | 0.19 | Why? |
| Young Adult | 20 | 2021 | 93724 | 0.18 | Why? |
| Host-Pathogen Interactions | 1 | 2019 | 11041 | 0.18 | Why? |
| Male | 42 | 2020 | 367725 | 0.18 | Why? |
| Female | 42 | 2020 | 380317 | 0.18 | Why? |
| Sequence Analysis, DNA | 5 | 2020 | 2830 | 0.17 | Why? |
| Adult | 34 | 2021 | 244371 | 0.17 | Why? |
| Fluorescent Antibody Technique, Indirect | 1 | 2019 | 393 | 0.17 | Why? |
| Staphylococcal Infections | 1 | 2007 | 1099 | 0.17 | Why? |
| Public Health Surveillance | 3 | 2020 | 3129 | 0.17 | Why? |
| Keratoconjunctivitis | 1 | 2017 | 41 | 0.17 | Why? |
| Humans | 72 | 2021 | 930598 | 0.17 | Why? |
| Coronaviridae | 2 | 2021 | 923 | 0.17 | Why? |
| Pneumonia, Pneumococcal | 1 | 2020 | 251 | 0.17 | Why? |
| Meningitis, Viral | 1 | 2018 | 97 | 0.16 | Why? |
| Contact Tracing | 8 | 2021 | 8448 | 0.16 | Why? |
| Enzyme-Linked Immunosorbent Assay | 4 | 2021 | 7868 | 0.16 | Why? |
| Middle Aged | 30 | 2020 | 270681 | 0.16 | Why? |
| Enterovirus A, Human | 1 | 2018 | 180 | 0.15 | Why? |
| Microbial Viability | 1 | 2020 | 406 | 0.15 | Why? |
| Infant, Newborn | 8 | 2020 | 23105 | 0.15 | Why? |
| Middle East | 3 | 2016 | 1418 | 0.15 | Why? |
| Disease Transmission, Infectious | 1 | 2019 | 9044 | 0.15 | Why? |
| Text Messaging | 1 | 2020 | 389 | 0.15 | Why? |
| Sequence Deletion | 1 | 2019 | 674 | 0.14 | Why? |
| Sequence Homology | 1 | 2016 | 448 | 0.14 | Why? |
| Aged, 80 and over | 13 | 2019 | 88759 | 0.14 | Why? |
| Enterovirus | 1 | 2018 | 402 | 0.14 | Why? |
| Aged | 21 | 2020 | 215776 | 0.13 | Why? |
| Travel | 9 | 2020 | 7220 | 0.13 | Why? |
| Family Health | 1 | 2019 | 731 | 0.13 | Why? |
| Intensive Care Units, Neonatal | 1 | 2019 | 749 | 0.12 | Why? |
| Sentinel Surveillance | 1 | 2020 | 1093 | 0.12 | Why? |
| Phylogeny | 8 | 2019 | 13341 | 0.12 | Why? |
| Models, Organizational | 1 | 2018 | 908 | 0.12 | Why? |
| Rhinovirus | 1 | 2018 | 979 | 0.12 | Why? |
| Rural Health Services | 1 | 2018 | 496 | 0.11 | Why? |
| Disease Reservoirs | 1 | 2021 | 1672 | 0.11 | Why? |
| Cluster Analysis | 2 | 2017 | 3001 | 0.11 | Why? |
| Seroconversion | 1 | 2021 | 2515 | 0.11 | Why? |
| Family | 2 | 2016 | 2909 | 0.11 | Why? |
| Molecular Epidemiology | 1 | 2016 | 1638 | 0.10 | Why? |
| Diagnostic Tests, Routine | 2 | 2021 | 2643 | 0.10 | Why? |
| Wisconsin | 2 | 2021 | 607 | 0.10 | Why? |
| Stillbirth | 1 | 2014 | 544 | 0.10 | Why? |
| Real-Time Polymerase Chain Reaction | 6 | 2021 | 11367 | 0.09 | Why? |
| Polymerase Chain Reaction | 3 | 2018 | 6740 | 0.09 | Why? |
| Antibody Formation | 1 | 2021 | 4038 | 0.09 | Why? |
| Nurseries, Hospital | 1 | 2007 | 26 | 0.09 | Why? |
| Electrophoresis, Gel, Pulsed-Field | 1 | 2007 | 78 | 0.09 | Why? |
| Cost-Benefit Analysis | 1 | 2017 | 2259 | 0.08 | Why? |
| Serologic Tests | 2 | 2017 | 4359 | 0.08 | Why? |
| Environmental Exposure | 1 | 2016 | 1558 | 0.08 | Why? |
| Washington | 2 | 2021 | 1722 | 0.07 | Why? |
| Seroepidemiologic Studies | 2 | 2019 | 10017 | 0.07 | Why? |
| Symptom Assessment | 1 | 2019 | 4967 | 0.07 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2020 | 13720 | 0.07 | Why? |
| Guidelines as Topic | 2 | 2015 | 2844 | 0.07 | Why? |
| Antibodies, Neutralizing | 3 | 2021 | 25288 | 0.07 | Why? |
| Chicago | 1 | 2007 | 653 | 0.07 | Why? |
| Animals | 10 | 2021 | 78931 | 0.07 | Why? |
| Asthma | 2 | 2020 | 4383 | 0.07 | Why? |
| Occupational Diseases | 1 | 2019 | 2787 | 0.06 | Why? |
| Genetic Variation | 1 | 2017 | 3919 | 0.06 | Why? |
| Clinical Laboratory Techniques | 5 | 2021 | 23402 | 0.06 | Why? |
| Betacoronavirus | 7 | 2021 | 204454 | 0.06 | Why? |
| Fatal Outcome | 3 | 2017 | 3438 | 0.06 | Why? |
| Spike Glycoprotein, Coronavirus | 5 | 2021 | 37182 | 0.06 | Why? |
| Coronavirus | 3 | 2018 | 18339 | 0.06 | Why? |
| Communicable Diseases, Emerging | 1 | 2016 | 2523 | 0.06 | Why? |
| Iowa | 1 | 2021 | 111 | 0.06 | Why? |
| Viral Load | 2 | 2019 | 15850 | 0.05 | Why? |
| Sepsis | 1 | 2018 | 3517 | 0.05 | Why? |
| Oregon | 1 | 2021 | 224 | 0.05 | Why? |
| History, 21st Century | 2 | 2019 | 1849 | 0.05 | Why? |
| Retrognathia | 1 | 2020 | 17 | 0.05 | Why? |
| Survival Analysis | 1 | 2014 | 7592 | 0.05 | Why? |
| Streptococcus | 1 | 2020 | 76 | 0.05 | Why? |
| Risk Factors | 6 | 2020 | 71621 | 0.05 | Why? |
| Primary Health Care | 1 | 2018 | 4839 | 0.05 | Why? |
| Rhode Island | 1 | 2021 | 425 | 0.05 | Why? |
| Infection Control | 6 | 2019 | 23131 | 0.05 | Why? |
| Mass Screening | 1 | 2020 | 8005 | 0.05 | Why? |
| Nervous System Diseases | 1 | 2018 | 4092 | 0.05 | Why? |
| Half-Life | 1 | 2020 | 298 | 0.05 | Why? |
| Genome, Viral | 5 | 2020 | 13157 | 0.05 | Why? |
| Connecticut | 1 | 2021 | 547 | 0.05 | Why? |
| United States Virgin Islands | 1 | 2017 | 8 | 0.05 | Why? |
| Illinois | 1 | 2020 | 468 | 0.05 | Why? |
| Virus Replication | 1 | 2019 | 14331 | 0.04 | Why? |
| North Dakota | 1 | 2017 | 21 | 0.04 | Why? |
| Hypertension | 1 | 2020 | 8895 | 0.04 | Why? |
| Louisiana | 1 | 2019 | 353 | 0.04 | Why? |
| Albania | 1 | 2017 | 58 | 0.04 | Why? |
| Nicaragua | 1 | 2017 | 71 | 0.04 | Why? |
| Diabetes Mellitus | 1 | 2020 | 8207 | 0.04 | Why? |
| Missouri | 1 | 2018 | 274 | 0.04 | Why? |
| Michigan | 1 | 2021 | 988 | 0.04 | Why? |
| Pneumonia, Viral | 6 | 2020 | 243684 | 0.04 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 9706 | 0.04 | Why? |
| Alberta | 1 | 2018 | 375 | 0.04 | Why? |
| Diabetes Mellitus, Type 2 | 1 | 2018 | 6166 | 0.04 | Why? |
| Whole Genome Sequencing | 2 | 2019 | 3239 | 0.04 | Why? |
| Colorado | 1 | 2018 | 434 | 0.04 | Why? |
| Epidemics | 1 | 2017 | 6407 | 0.04 | Why? |
| 5' Untranslated Regions | 1 | 2019 | 375 | 0.04 | Why? |
| Genotype | 2 | 2019 | 4697 | 0.04 | Why? |
| Massachusetts | 1 | 2021 | 1279 | 0.04 | Why? |
| RNA, Viral | 3 | 2019 | 32276 | 0.04 | Why? |
| Alphacoronavirus | 1 | 2021 | 392 | 0.04 | Why? |
| Mothers | 1 | 2007 | 1624 | 0.04 | Why? |
| SARS Virus | 1 | 2020 | 13021 | 0.04 | Why? |
| Host Specificity | 1 | 2021 | 926 | 0.04 | Why? |
| Hospitals | 1 | 2016 | 11793 | 0.04 | Why? |
| Acute Disease | 2 | 2020 | 6029 | 0.04 | Why? |
| Public Health Administration | 2 | 2015 | 846 | 0.04 | Why? |
| Blood Chemical Analysis | 1 | 2020 | 541 | 0.04 | Why? |
| Health Personnel | 5 | 2019 | 29646 | 0.04 | Why? |
| Residential Facilities | 1 | 2020 | 443 | 0.04 | Why? |
| Ohio | 1 | 2017 | 639 | 0.03 | Why? |
| Serotyping | 1 | 2014 | 154 | 0.03 | Why? |
| Medical Records | 1 | 2017 | 513 | 0.03 | Why? |
| Philippines | 1 | 2017 | 568 | 0.03 | Why? |
| Incidence | 4 | 2018 | 25622 | 0.03 | Why? |
| Prospective Studies | 4 | 2021 | 43301 | 0.03 | Why? |
| Africa, Western | 1 | 2015 | 363 | 0.03 | Why? |
| Personnel, Hospital | 1 | 2007 | 2273 | 0.03 | Why? |
| Animals, Wild | 1 | 2021 | 1028 | 0.03 | Why? |
| Lung | 2 | 2020 | 31049 | 0.03 | Why? |
| Respiratory Syncytial Viruses | 1 | 2017 | 612 | 0.03 | Why? |
| Tunisia | 1 | 2014 | 543 | 0.03 | Why? |
| Adenoviridae | 1 | 2019 | 1151 | 0.03 | Why? |
| Open Reading Frames | 1 | 2019 | 1898 | 0.03 | Why? |
| Florida | 1 | 2014 | 598 | 0.03 | Why? |
| Travel-Related Illness | 1 | 2020 | 1357 | 0.03 | Why? |
| Influenza, Human | 1 | 2017 | 10779 | 0.03 | Why? |
| Pediatricians | 1 | 2016 | 401 | 0.03 | Why? |
| Metagenomics | 1 | 2017 | 823 | 0.03 | Why? |
| Nose | 1 | 2017 | 1093 | 0.03 | Why? |
| Antigens, Viral | 2 | 2018 | 6298 | 0.03 | Why? |
| Family Characteristics | 1 | 2021 | 2551 | 0.03 | Why? |
| Feasibility Studies | 1 | 2020 | 3467 | 0.03 | Why? |
| Recombination, Genetic | 1 | 2017 | 1265 | 0.03 | Why? |
| Base Sequence | 1 | 2019 | 3581 | 0.03 | Why? |
| Bayes Theorem | 1 | 2020 | 3237 | 0.03 | Why? |
| Pregnancy Complications, Infectious | 1 | 2016 | 11559 | 0.03 | Why? |
| Glycated Hemoglobin A | 1 | 2018 | 1316 | 0.03 | Why? |
| Pharynx | 1 | 2017 | 1544 | 0.02 | Why? |
| Surveys and Questionnaires | 1 | 2017 | 43792 | 0.02 | Why? |
| China | 3 | 2021 | 50654 | 0.02 | Why? |
| Hospitalization | 2 | 2017 | 54280 | 0.02 | Why? |
| Severity of Illness Index | 1 | 2017 | 48226 | 0.02 | Why? |
| Communicable Disease Control | 2 | 2016 | 29620 | 0.02 | Why? |
| Dipeptidyl Peptidase 4 | 1 | 2016 | 1061 | 0.02 | Why? |
| Military Personnel | 1 | 2019 | 1097 | 0.02 | Why? |
| Pilot Projects | 1 | 2020 | 5182 | 0.02 | Why? |
| Immunohistochemistry | 1 | 2016 | 2275 | 0.02 | Why? |
| Long-Term Care | 1 | 2020 | 2047 | 0.02 | Why? |
| Health Care Surveys | 1 | 2017 | 2942 | 0.02 | Why? |
| Radiography | 1 | 2016 | 1576 | 0.02 | Why? |
| Blood Donors | 1 | 2021 | 2956 | 0.02 | Why? |
| Genomics | 1 | 2019 | 3118 | 0.02 | Why? |
| Cooperative Behavior | 1 | 2015 | 1216 | 0.02 | Why? |
| Retrospective Studies | 2 | 2016 | 105322 | 0.02 | Why? |
| Immunoglobulin G | 2 | 2021 | 21571 | 0.02 | Why? |
| Blood Pressure | 1 | 2018 | 2198 | 0.02 | Why? |
| New York City | 1 | 2020 | 7432 | 0.02 | Why? |
| Hospitals, Pediatric | 1 | 2017 | 1792 | 0.02 | Why? |
| Rural Population | 1 | 2018 | 2408 | 0.02 | Why? |
| Prevalence | 2 | 2018 | 25773 | 0.02 | Why? |
| Body Mass Index | 1 | 2018 | 4306 | 0.02 | Why? |
| Fever | 1 | 2021 | 7795 | 0.02 | Why? |
| Pandemics | 6 | 2021 | 389249 | 0.02 | Why? |
| Cell Line | 1 | 2019 | 12040 | 0.02 | Why? |
| Risk Assessment | 2 | 2020 | 25439 | 0.02 | Why? |
| Aerosols | 1 | 2020 | 5393 | 0.02 | Why? |
| Virus Shedding | 1 | 2020 | 5834 | 0.02 | Why? |
| Ophthalmology | 1 | 2017 | 1840 | 0.02 | Why? |
| Pregnancy Outcome | 1 | 2016 | 3803 | 0.02 | Why? |
| Radiography, Thoracic | 1 | 2020 | 5486 | 0.02 | Why? |
| Follow-Up Studies | 1 | 2021 | 17020 | 0.02 | Why? |
| Databases, Factual | 1 | 2018 | 6248 | 0.02 | Why? |
| Pregnancy | 2 | 2016 | 23879 | 0.02 | Why? |
| World Health Organization | 1 | 2015 | 4213 | 0.01 | Why? |
| Immunoassay | 1 | 2017 | 4485 | 0.01 | Why? |
| Nasopharynx | 1 | 2021 | 10224 | 0.01 | Why? |
| Disease Progression | 1 | 2020 | 13580 | 0.01 | Why? |
| Patient Isolation | 1 | 2014 | 3182 | 0.01 | Why? |
| Algorithms | 1 | 2017 | 7346 | 0.01 | Why? |
| Disease Management | 1 | 2018 | 6841 | 0.01 | Why? |
| Practice Guidelines as Topic | 2 | 2015 | 15421 | 0.01 | Why? |
| Practice Patterns, Physicians' | 1 | 2017 | 4927 | 0.01 | Why? |
| Coinfection | 1 | 2018 | 6820 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2018 | 22971 | 0.01 | Why? |
| Communication | 1 | 2015 | 5206 | 0.01 | Why? |
| Case-Control Studies | 1 | 2016 | 17671 | 0.01 | Why? |
| Age Factors | 1 | 2018 | 21039 | 0.01 | Why? |
| Viral Vaccines | 1 | 2017 | 7560 | 0.01 | Why? |
| Biomarkers | 1 | 2018 | 23361 | 0.01 | Why? |
| Critical Care | 1 | 2018 | 14081 | 0.01 | Why? |
| Public Health | 1 | 2020 | 16359 | 0.01 | Why? |
| Comorbidity | 1 | 2018 | 34796 | 0.01 | Why? |
| Time Factors | 1 | 2016 | 31397 | 0.01 | Why? |
| Treatment Outcome | 1 | 2014 | 51732 | 0.01 | Why? |
| Antiviral Agents | 1 | 2017 | 41703 | 0.00 | Why? |